Onco Actu du 5 avril 2016

	3.1 Tabac
India steps up fight against Big Tobacco over health warnings [Reuters] The government wants manufacturers to cover 85 percent of a cigarette pack's surface in health warnings, up from 20 percent now. But ITC Ltd, part-owned by British American Tobacco, and Godfrey Phillips, partner of U.S.-based Philip Morris International, have opposed the measure, saying a parliament panel had suggested the health warning to be half the cigarette pack's size.
	4.5 Dép., diag. & prono. - Colorectal
A Teachable Moment on the Need for Colon Cancer Screening [NY Times] The goal of this National Colorectal Cancer Roundtable, as it is called, is to get 80 percent of Americans screened for colorectal cancer by 2018.
	5. Traitements
Targeting two angiogenesis pathways could improve results of glioblastoma treatment [Massachusetts General Hospital] Appearing in PNAS Early Edition, the reports describe how two different methods of inhibiting both vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) in animal models not only normalized tumor blood vessels to a greater extent than anti-VEGF therapy alone but also shifted the action of tumor-infiltrating immune cells from a pro-tumor to an anti-tumor state.
	5.2 Pharma
Did Clovis play a deceptive game with rociletinib data in leadup to its PhIII stunner? [FierceBiotech] New analysis published in the Annals of Oncology raises serious questions about the truthfulness and timing involved in the way Clovis Oncology corrected pivotal data on its cancer drug rociletinib.
	5.3 Traitements - FDA, EMA,...
Better safety for patients through EU-funded research [EMA] The goal of this project was to develop innovative methods to improve and strengthen the monitoring of the benefits and risks of medicines marketed in the European Union.
Extrapolation of data from adults to children can facilitate development of paediatric medicines [EMA] The draft reflection paper outlines a systematic approach to extrapolation of data from adults or other paediatric populations to children that is considered scientifically sound and reliable to support the authorisation of a medicine. The framework sets out when, to what extent, and how extrapolation can be applied and validated.
	5.4 Traitements - Economie
Harvard, Tufts med students stage protest at 'biased' $2.9B drug development figure [FierceBiotech] Around two dozen students from Harvard Medical School and Tufts University as well as members of health activist groups protested in front of the Tufts Center for the Study of Drug Development claiming new figures suggesting bringing a new drug to market costs nearly $3 billion came from a "biased" report.
Exclusive: Makers took big price increases on widely used U.S. drugs [Reuters] Major drug companies took hefty price increases in the U.S., in some cases more than doubling listed charges, for widely used medications over the past five years, a Reuters analysis of proprietary data found.
	6.1 Observation
Good economy? More bowel cancers [CNN] Arnold's team analyzed rates of colorectal cancer across all levels of the Human Development Index (HDI) in 184 countries and found that the higher the HDI, the higher the rates of bowel cancer. Countries with a very high HDI had levels, on average, six time higher than countries with a low HDI.
	6.10 Politiques
Twenty AACR Members Selected to NCI Blue Ribbon Panel to Guide Vice President Biden’s National Cancer Moonshot Initiative [AACR] The AACR will provide a global platform for Vice President Biden to expand on his vision when he delivers remarks on Wednesday, April 20, during the AACR Annual Meeting, "Highlights 2016: Vision for the Future" Plenary Session, which will also be available via live webcast.
Blue Ribbon Panel Announced to Help Guide Vice President Biden’s National Cancer Moonshot Initiative [National Institutes of Health] Over the next several months, the panel will consider how to advance the themes that have been proposed for the initiative. The themes include the development of cancer vaccines, highly sensitive approaches to early detection, advances in immunotherapy and combination therapies, single-cell genomic profiling of cancer cells and cells in the tumor microenvironment, enhanced data sharing, and new approaches to the treatment of pediatric cancers.
Scientific advisers tapped to guide Biden’s cancer moonshot [Science] The advisory board will take ideas from the public and hold a summit later this spring to discuss collaborations with industry.
Breaking News: Jacks, Jaffee, Singer Named Co-Chairs of NCI’s Moonshot Blue Ribbon Panel [The Cancer Letter] NCI has formed a panel of advisors to inform the scientific direction and goals of Vice President Joe Biden’s National Cancer Moonshot Initiative.
	6.9 Controverses
Better late than never: Orac comments on the hijacking of evidence-based medicine [Respectful Insolence] What we have a problem with in EBM is the methodolatry that has come to dominate the core of EBM that leads EBM purists to refuse to dismiss obvious quackery like homeopathy and “energy medicine.”